Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-4/RTOG-3515 durvalumab or osimertinib after SBRT in unresected early-stage NSCLC
NL-OMON54495Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + SoC SBRT, Placebo + SoC SBRT and Osimertinib + SoC SBRT cohort (3 arms). Primary endpoints: Progression-free survival in main durvalumab cohort subset and Four-year progression-free survival in osimertinib cohort. Started Jan 2020; status: recruiting.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54495.